Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 17/20 | 0.73 |
| ▸ | PYGM | P11217 | 12/20 | 0.73 |
| ▸ | FLT3 | P36888 | 2/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.48 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5643030 | 0.86 | PYGL (0.77) | PYGLPYGMSMYD3 | |
| SCHEMBL4803861 | 0.84 | PYGL (1.00) | PYGLPYGM | |
| SCHEMBL4796608 | 0.84 | PYGL (1.00) | PYGLPYGM | |
| SCHEMBL4803919 | 0.84 | PYGL (1.00) | PYGLPYGM | |
| SCHEMBL14380805 | 0.83 | PYGL (0.73) | PYGLPYGM | |
| SCHEMBL4797974 | 0.81 | PYGL (0.69) | PYGLPYGMSMYD3 | |
| SCHEMBL4801410 | 0.77 | PYGL (1.00) | PYGLPYGMSMYD3 | |
| SCHEMBL14064260 | 0.76 | PYGL (0.72) | PYGLPYGMSMYD3 | |
| SCHEMBL4795783 | 0.75 | PYGL (0.74) | PYGLPYGM | |
| SCHEMBL4802668 | 0.75 | PYGL (0.74) | PYGLPYGM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050131016-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2005-06-16 | — | — | US | claimed |
| EP-1485371-A2 | INDOLE AMIDE DERIVATIVES AND THEIR USE AS GLYCOGEN PHOSPHORYLASE INHIBITORS | AstraZeneca AB (SE) | 2004-12-15 | — | — | EP | claimed |
| WO-2003074513-A2 | INDOLE AMIDE DERIVATIVES AND THEIR USE AS GLYCOGEN PHOSPHORYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2003-09-12 | — | — | WO | claimed |
| US-7169927-B2 | Indole-amide derivatives and their use as glycogen phosphorylase inhibitors | ASTRAZENECA AB (SE) | 2007-01-30 | — | — | US | disclosed |
| US-20050131016-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2005-06-16 | — | — | US | disclosed |
| EP-1485371-A2 | INDOLE AMIDE DERIVATIVES AND THEIR USE AS GLYCOGEN PHOSPHORYLASE INHIBITORS | AstraZeneca AB (SE) | 2004-12-15 | — | — | EP | disclosed |
| WO-2003074513-A2 | INDOLE AMIDE DERIVATIVES AND THEIR USE AS GLYCOGEN PHOSPHORYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131016-A1 | Chemical compounds | PYGL, GYS1, CA9 | PYGL 1/4885PYGM 5/4885FLT3 4193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.